middle.news
Dimerix Secures $30M Upfront in Landmark US License Deal for Kidney Disease Drug
3:38am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Dimerix Secures $30M Upfront in Landmark US License Deal for Kidney Disease Drug
3:38am on Monday 2nd of June, 2025 AEST
Key Points
Exclusive US commercialization rights for DMX-200 licensed to Amicus Therapeutics
Dimerix receives $30 million upfront plus up to $560 million in milestone payments
FDA aligns on proteinuria as primary endpoint for DMX-200 approval in FSGS
DMX-200 Phase 3 ACTION3 trial progressing with full enrollment expected by end 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE